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while NASH management options focus on lifestyle changes, based on diet and exercise, and control of the associated comorbidities. 2, 10 Lifestyle changes have demonstrated greatest benefit in improving steatosis and mild fibrosis; 2,10 however, as patients with advanced fibrosis due to NASH are at a significantly higher risk of liver-related mortality, pharmacological treatments are urgently needed, especially in this population. 11 Fibrosis is considered the strongest predictor of adverse clinical outcomes, including liver-related death. 12, 13 Therefore, fibrosis improvement has been identified as an important endpoint in clinical trials by regulatory agenciesthe Food and Drug Administration (FDA) has recently developed draft guidance detailing that Phase II trials should provide evidence of efficacy on a histological endpoint such as reduction in inflammatory changes, improvement in fibrosis, or both. 13 This guidance showcases the need for approved therapies in NASH, specifically in fibrosis due to NASH.
In order to understand the current treatment landscape in NASH, this structured literature review aimed to identify all management options in use for patients with NASH and examine the clinical outcomes achieved.
| ME THODOLOGY
A structured literature review was conducted to identify literature on the current management and treatments in NASH, including all available safety and efficacy data. A pre-agreed search protocol was used, following the principles of the Cochrane handbook for systematic literature reviews (SLRs). 14 The OVID search engine was used to search for publications across 4 databases: EconLit, Embase, PsycINFO, and Medline. The search strategy used a combination of free-text searching and "subject headings" to ensure that the most relevant literature was identified (see Appendix S1).
Searches were limited to English language publications between 1 January 2007 and 25 September 2017. Publications were included in the full-text review if they reported on the efficacy or safety of treatments or lifestyle management in adult patients (≥18 years) with NASH.
To ensure all relevant publications were captured, a "grey literature" search was performed. This included an internet-based search using a combination of efficacy, safety and management keywords and incorporated both nonpeer-reviewed, publicly available information and peer-reviewed publications that may not yet be indexed in OVID databases, due to their recent publication date, or because they were published in journals that are not indexed within these da- 
| RE SULTS
There was a wide range of study types identified, including metaanalyses, randomized controlled trials (RCTs), narrative reviews, and observational studies. The publications identified varied in robustness; small studies with short follow-up, and RCTs of limited quality were the most frequently identified. Where available, the study design and number of included patients have been reported in this manuscript for clarity.
The captured publications confirmed that the current management of NASH includes lifestyle modification, off-label treatments, bariatric surgery, and LT. Lifestyle modification was the most commonly reported management strategy in NASH and was the mainstay of treatment in the absence of approved therapies. 10, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Multiple publications also discussed off-label therapy use; however, as these focused on the treatment of comorbidities due to NASH, relevant data were limited. 10, 15, 20, 23, 26, 27 In contrast, few publications reported on bariatric surgery and LT, with ten reporting on these interventions. 16, [28] [29] [30] [31] [32] [33] [34] [35] [36] An overview of the NASH management strategies identified in this review are presented in Figure 2 .
| Lifestyle modification
Lifestyle modification was identified as the main method for the nonclinical management of NASH, with 12 publications reporting on this. 10, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Outcomes related to weight loss were reported in 5 publications, including a Phase III RCT (n = 31), a narrative review, and a prospective (n = 293), retrospective (n = 45) cohort study, and Practice Guidance. 15, 16, 18, 21, 24 The publications indicated that weight loss was associated with several clinical improvements, including improvements in liver histology, lobular inflammation, fibrosis resolution, and fibrosis progression. 15, 18, 21, 24 The specific outcomes achieved with lifestyle modification are shown in Table 1 . Four original research publications are referenced in Table 1 to support the data points cited in the captured publications. [37] [38] [39] [40] In addition to the clinical improvements of weight loss, the AASLD Practice Guidance, which provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD and NASH care, reported that a weight loss of 3%-5%
improved steatosis, but a greater weight loss of 7%-10% showed a significant improvement in all features of NASH, including portal inflammation and fibrosis. 16 One narrative review suggested that a weight loss of ≥7% may improve liver histology in NASH patients based on observations from small studies conducted in patients with fatty liver or coronary heart disease. 15 While weight loss was acknowledged by the Practice Guidance as a good management option to improve steatosis, one narrative review highlighted that a key difficulty in NASH was not achieving weight loss, but rather maintaining it. 17 The authors cautioned that this issue has not been addressed in the context of NASH, which correlated with the findings of this narrative review, as no publication reported on maintaining weight loss in patients with NASH. 17 Weight loss management was further stratified into diet composition and caloric restriction in the literature. One SLR reported that caloric restriction was the most important lifestyle modification to induce weight loss and improve steatosis. 25 The SLR also reported that diet composition induces the greatest F I G U R E 1 PRISMA diagram of included and excluded publications. PRISMA, preferred reporting items for systematic reviews and meta-analyses 
| Off-label treatments in NASH
There are currently no therapies indicated for use in patients with NASH; therefore, all captured publications reported on their off-label therapy use only. While the identified AASLD Practice
Guidance recommended the consideration of pioglitazone (PIO) and/or vitamin E as pharmacological options for some patients with NASH, these are also not indicated in NASH and are used off-label. 16 There was a range of outcomes captured for these therapies and the specific outcomes reported (where available) are presented in Table 2 . Ten original research publications are referenced in Table 2 to support the data points cited in the captured publications. 6 months Significant difference to the histopathological profile overall (P < 0.001).
BP, blood pressure; FBS, fasting blood sugar; HOMA-IR, homeostasis model of insulin resistance; HS, hepatic steatosis; NAFLD, nonalcoholic fatty liver disease; NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis; NR, not reported; QoL, quality of life; RCT, randomized controlled trial; TG, triglycerides; US, United States; vs, versus. with improvements in steatosis, inflammation, and ballooning in nondiabetic patients with NASH; this was supported by a meta-analysis (n = 401) (Sato et al., 2015) and a narrative review (n = 247) which also showed improvements in steatosis (see Table 2 ). 10, 27 However, discrepancies were identified as to whether vitamin E leads to fibrosis improvement: the meta-analysis reported that vitamin E improved both hepatic histology and fibrosis, 27 whereas the narrative review reported no change in fibrosis with vitamin E. 10 In addition, this review raised concerns about the safety profile of vitamin E due to possible increases in mortality and prostate cancer; however, the authors noted that the studies reporting this were small in size, and
were not powered to test safety hypotheses. 
| Thiazolidinediones (including Pioglitazone)
The thiazolidinedione, pioglitazone (PIO), was the most frequently reported off-label treatment in NASH, and was captured in 6 publications. 10, 23, [51] [52] [53] [54] In these publications, PIO showed an improvement in steatosis and inflammation and a smaller improvement in fibrosis in patients with NASH (see Table 2 ). 10,23,52 However, variable efficacy was reported: a narrative review (n = 247) in patients with nondiabetic NASH reported that PIO did not meet the primary endpoint of significant changes in histological features, as assessed by the CRN classification in a Phase III RCT suggesting the use of PIO may be limited in NASH. 23 Despite its failure to reach the primary endpoint, a reduction in hepatic steatosis (P < 0.001) and lobular inflammation (P < 0.001) was observed. 23 This was also seen in another Phase III RCT (n = 60) of PIO versus (vs) pentoxifylline (PTX), where significant improvements in hepatic steatosis were reported (see section 3.2.7). 51 In a meta-analysis, PIO was associated with increased odds of advanced fibrosis improvement (odds ratio (OR), 2.95; 95%CI, 1.04-10.90) vs placebo (PBO) (P = 0.02), suggesting PIO may be one of the few therapies identified that are efficacious in this population. 54 Additional long-term safety concerns in NASH were discussed based on studies conducted in patients with diabetes: a narrative review reported that PIO was associated with an increased risk of heart failure, bone fracture, oedema, and weight gain; 23 however, another narrative review found that PIO reduced the risk of major cardiovascular events (myocardial infarction, stroke and cardiovascular death), suggesting that the long-term safety profile of PIO remains to be established in NASH. 10 Conflicting data were also reported on the clinical use of thiazolidinediones; one Phase II RCT (n = 40) reported no significant benefit with long-term use of the thiazolidinedione, rosiglitazone (which has subsequently been withdrawn from use). 53 Additionally, a narrative review reported that discontinuation of thiazolidinediones resulted in a return to pretreatment NASH histology, suggesting that PIO therapy would have to be maintained indefinitely to sustain a treatment response; however, no efficacy or safety data were reported. 
| Liraglutide
A narrative review (n = 52) and the AASLD Practice Guidance reported on the efficacy of liraglutide in patients with NASH. 10, 16 Both publications showed patients had improved resolution of NASH as well as small improvements in fibrosis progression (see Table 2 ). 10, 16 In addition, the Practice Guidance noted that although liraglutide was associated with weight loss, gastrointestinal effects were reported. 
| Metformin
One narrative review reported on clinical outcomes of metformin in NASH. 15 The identified review described improvements in serum aminotransferases for patients treated with metformin; however, no results were presented. 15 Additionally, the review described no significant benefit of metformin in improving liver histology in patients with NASH. 15 No other efficacy and safety data were reported.
| Obeticholic acid
Three publications reported on clinical outcomes of obeticholic acid (OCA), showing improvements in steatosis, inflammation, and fibrosis for patients with noncirrhotic NASH as well as patients with NASH and comorbid T2DM (see Table 2 ). 20, 55, 56 However, a secondary analysis of the FLINT trial (n = 198) reported that these improvements were associated with significant increases in LDL-C in patients with noncirrhotic NASH, which was a concern due to NASH alone being associated with increased cholesterol synthesis. 56 One narrative review (n = 219) examining both OCA and intestinal-specific Farnesoid X receptor (FXR) agonists in NASH reported that intestinal-specific FXR may reduce obesity, improve peripheral, and hepatic insulin resistance and reduce liver inflammation in patients with NASH. 20 However, the authors concluded that further studies and long-term data are required to assess the clinical efficacy of this treatment in improving hepatic fibrosis in patients with NASH. 20 The authors also suggested that this treatment may not have an associated increase in LDL-C and HDL-C observed with OCA; however, the treatments were not directly compared and thus require further investigation. 
| Ursodeoxycholic acid
One retrospective cohort study (n = 101), one SLR and the AASLD Practice Guidance reported on clinical outcomes of ursodeoxycholic acid (UDCA) ( Table 2) . 16, 57, 58 The retrospective cohort study (n = 101)
reported that UDCA in combination with vitamin E showed an improvement in long-term liver function tests. 57 This was supported by the SLR, reporting that the same combination therapy significantly improved liver function in 5 small proof-of-concept studies in patients with NASH. 58 The Practice Guidance concluded that despite promising results, UDCA has so far only been investigated in proofof-concept studies with a small number of participants and with surrogate endpoints; therefore, the efficacy data should be interpreted with caution. 16 
| Pentoxifylline
Two RCTs (n = 60 and n = 35) and a narrative review reported that PTX improved histological features of NASH, but showed no significant benefit in improving fibrosis (see Table 2 ). 51, 59, 60 The first Phase II RCT (n = 35) examined PTX vs PBO, with PTX showing significant improvements in liver histology with minimal side effects, including abdominal pain. 60 The other Phase II RCT (n = 60) examined PTX vs PIO and while both treatments showed significant improvements in hepatic steatosis, the authors concluded that due to greater improvements in patients with NASH, PIO should be used ahead of PTX. 
| Statins
A narrative review and a cross-sectional study (n = 347) reported on clinical outcomes of statins. 33, 61 The review showed that statins had potential beneficial effect in patients with NASH cirrhosis, as an improvement in liver function tests was observed in this population, possibly delaying decompensation. 33 However, the cross-sectional study reported worsening of fibrosis and NASH progression in patients with NASH and comorbid T2DM (although the results were not significant). 61 In addition to the above studies, a Phase II RCT investigating the effects of atorvastatin and L-carnitine co-administration vs atorvastatin was identified. 
| Angiotensin II receptor antagonists
One narrative review reported on clinical outcomes of angiotensin II receptor antagonists (ARBs). 59 In the review, ARBs were shown to improve serum transaminases in patients with NASH and hypertension. 59 It also reported on telmisartan, an ARB which has shown beneficial effects on steatosis, ballooning, lobular inflammation, and fibrosis in small studies, although the authors cautioned more histological data are required to confirm this. 
| Conclusions
Off-label treatments in NASH are focused on treating comorbidities such as T2DM and obesity. PIO and vitamin E are the only pharmacological therapies currently recommended off-label for NASH patients. Marketed therapies (ie metformin, liraglutide, angiotensin II receptor antagonists, statins, OCA, pentoxifylline and UDCA) are often used off-label; however, due to lack of data, are not currently recommended in NASH patients.
| Investigational treatments
A number of investigational treatments were identified for the treatment of NASH, including: aramchol, BMS-986036, BMS-986263, cenicriviroc, elafibranor, GS-0976, Imm-124E, NGM282, and selonsertib. These investigational treatments had limited efficacy and safety data available (details of the reported safety and efficacy outcomes are presented in Table 2 ). 10, 16, 26 Three original research publications are referenced in Table 2 to support the data points cited in the captured publications. [62] [63] [64] A narrative review showed that aramchol significantly decreased liver fat content in patients treated with 100 mg daily vs PBO in a Phase II RCT (n = 66) ( Table 2) . 10 However, minor adverse events were reported, namely mild abdominal pain and mild upper respiratory tract infection. 10 Preliminary data from a Phase II RCT (n = 74) and a post-hoc analysis (n = 48), showed a beneficial effect of BMS-986036 on steatosis, liver injury, and fibrosis in NASH; however, no safety data were reported (Table 2) . 65, 66 Preliminary data from a Phase Ib/II RCT (n = 11)
for a similar therapy, BMS-986263, have shown an improvement in advanced fibrosis in patients with NASH, with no dose-limiting toxicities reported (Table 2) . 67 A narrative review reported that cenicriviroc failed to meet the primary endpoint of a 2-point reduction in NAFLD activity score (NAS) in a Phase IIb trial; however, an improvement in fibrosis by at least one stage without worsening of steatosis was described. 26 Additionally, one cohort study (n = 1,022) noted that cenicriviroc had demonstrated a positive safety profile in patients with NASH, although long-term efficacy data were not reported for this (Table 2) . 68 The narrative review also reported on another therapy, elafibranor which failed to meet its primary endpoint of percentage disappearance of NASH without worsening of fibrosis in a Phase II RCT. 26 The endpoint was met in a sub-population of patients with mild-to-moderate fibrosis (NAS > 4) only; however, no further efficacy results were reported. 16, 26 In the AASLD Practice Guidance, elafibranor was associated with improving NASH without the worsening of fibrosis over a 12-month period. 16 Additionally, although elafibranor was associated with improved cardiometabolic profiles, there was a mild, reversible increase in serum creatinine. 16 In a Phase II RCT of GS-0976 (n = 49) vs PBO (n = 26), GS-0976
showed a significant reduction in magnetic resonance imagingproton density fat fraction (MRI-PDFF) in patients with NASH (Table 2) . 69 Furthermore, treatment with GS-0976 was associated with minimal side effects, the most frequent being nausea, abdominal pain, and diarrhoea. 69 A narrative review (n = 10) identified Imm124-E as an investigational treatment with very limited results: it was reported to mediate a reduction in haemoglobin A1C, insulin resistance and cause a mild improvement in cholesterol levels and liver enzymes in patients with NASH and comorbid T2DM (Table 2) . 10 NGM282 was another investigational treatment identified with limited results. 70 A post-hoc analysis (n = 82) reported that NGM282 showed significant reductions in hepatic steatosis, liver fat content and other NASH biomarkers; however, no safety data were captured. 70 In a Phase II RCT of selonsertib with simtuzumab (n = 62) vs simtuzumab alone (n = 10), selonsertib demonstrated a reduction in liver fibrosis in patients with NASH (Table 2) . 71 The majority of patients treated with selonsertib and simtuzumab experienced at least 1 mild-to-moderate adverse event, the most frequent being headache, nausea, and sinusitis. 71 An additional 12 investigational treatments were identified as being in early phases (Phase I/II) of development, with no safety or efficacy data reported. These treatments are summarized in Appendix S5.
| Conclusions
Overall , 
| Surgical treatments

| Bariatric surgery
In comparison to interventions used and described thus far, bariatric surgery was reported as a high cost treatment option used only in selected eligible patients with NASH to facilitate weight loss. 72 Six publications, including 3 prospective cohort studies (n = 109, n = 44 and n = 28), one meta-analysis, one narrative review, and the AASLD Practice Guidance discussed bariatric surgery. 16, [28] [29] [30] [31] [32] In all publications identified, bariatric surgery was reported to improve steatohepatitis, inflammation, and hepatocellular ballooning, as well as induce remission of T2DM, and NASH disappearance in morbidly obese patients and patients with cirrhotic NASH (see Table 3 ). [28] [29] [30] 32 In the meta-analysis of 766 paired liver biopsies, bariatric surgery was also reported to improve fibrosis due to NASH. 31 Despite the above results, the AASLD Practice Guidance recommended restricting the use of bariatric surgery to eligible obese patients with NASH only; therefore, limiting its use to a very small population. 16 One narrative review reported on emerging endoscopic bariatric therapies, including intragastric balloon therapy, which has been associated with equal weight loss and lower morbidity compared to conventional bariatric surgery. 10 Intragastric balloon therapy in combination with diet and exercise (n = 8) showed significant improvement in NAS at 6 months compared to a sham balloon placement (P = 0.03), as well as an improvement in QoL in obese patients (n = 119) after balloon placement (P < 0.05). 10 However, no change in hepatic inflammation, ballooning or fibrosis was reported. 
| Liver transplantation
LT in NASH was reported in 5 publications, including 2 retrospective cohort studies (n = 39,124 and n = 48), 2 narrative reviews and the AASLD Practice Guidance, where it was considered as an option for patients with NASH and ESLD or HCC only. 16, [33] [34] [35] [36] There were no efficacy data reported in any of the publications; however, 40% of patients with NASH were identified to be at risk of developing renal dysfunction within 1 month of LT, suggesting serious safety issues with LT in this patient population. 16, 35 Additional evidence from a clinical review suggested that reduction in risk factors for post-LT metabolic syndrome may impose a significant survival benefit in post-LT patients. 
| D ISCUSS I ON AND CON CLUS I ON S
A total of 48 publications were included in this literature review, which reported on the management strategies in NASH and the outcomes achieved with lifestyle modification, off-label therapies, investigational therapies, bariatric surgery, and LT. The majority of the publications presented were narrative reviews; therefore, the discrete data for the efficacy and safety of pharmacological therapies were limited or often lacking. In addition, the majority of the identified eligible publications (n = 34) were identified as grey literature, most were early findings in abstracts and were not yet peer-reviewed.
Although several publications reported that weight loss through lifestyle modification was associated with improvements in NASH, a reduction of 7%-10% was required to improve fibrosis, with greater improvements observed with increased weight loss: in patients who achieved weight loss of > 10%, almost half achieved fibrosis regression. 15, 18, 21, 24 With several difficulties associated with weight loss, including fatigue, lack of confidence to perform exercise and the high inability of maintaining weight loss long-term, it would appear that this management strategy is effective in the short-term only. 23, 25 There was a general lack of data on the long-term effects of lifestyle modification on NASH progression; therefore, further Despite this, the results of this review show that vitamin E use appears to be limited to patients with nondiabetic NASH due to lack of data in the overall NASH population. 16 Therefore, further research is required on the efficacy and safety of vitamin E before firm conclusions can be made regarding its use in NASH. Similarly, further research is required to address long-term safety concerns associated with PIO, as it was associated with an increased risk of heart failure, bone fracture, oedema and weight gain. 23 Conflicting data on the long-term efficacy of PIO may limit its use further, with the discontinuation of PIO therapy in patients reportedly leading to a return of pretreatment NASH histology, suggesting PIO may not be a reliable treatment for patients with NASH. 52, 53 Other off-label therapies were reported less frequently and 4 of these therapies (metformin, PTX, statins and UDCA) did not show or report improvements in fibrosis. As this is now considered a key efficacy endpoint in NASH, it would appear that most therapies require more research to show efficacy in this disease. 13 Only PIO has been studied in patients with advanced fibrosis due to NASH; however, it has also shown limited efficacy, warranting further clinical research for these patients. 10, 27 For investigational therapies in development for the treatment of NASH, the majority of data were small studies (n < 100), had There was a particularly limited evidence base for LT found as part of this review, with no publications reporting on the efficacy of LT in patients with NASH and one publication quoting safety concerns post-LT. 16 This may be due to studies rarely classifying NASH as the primary cause of LT, rather quoting liver disease, cancer or liver failure as reasoning for transplantation. Therefore, further research into the primary cause of LT is needed to understand its efficacy in NASH patients.
New techniques in endoscopic bariatrics, such as intragastric balloon therapy, have also been investigated due to the decrease in morbidity compared to bariatric surgery. 10 As these are relatively new potential options in NASH, further research is needed to determine their long-term effects and validate their cost-effectiveness. Should long-term effects be demonstrated, the NASH population eligible to receive these therapies will still remain extremely limited, further demonstrating a need for effective pharmacological therapies in early and later stages of NASH. Only one meta-analysis reported an improvement of bariatric surgery on liver fibrosis due to NASH, suggesting a lack of research in later stages of NASH with current surgical treatments. Due to the serious consequences associated with advancing NASH, including ESLD and HCC, new pharmacological therapies are needed to treat, reverse and halt fibrosis progression, thus reducing the costly consequences of this burdensome condition. 7 Due to the structured nature of this review, its methodology lacked a critical appraisal of data for each examined publication-this could lead to a skewed weighing of evidence (eg results from a network meta-analysis and a narrative review could be considered of equal quality); however, by reporting study design and size throughout the manuscript and only contrasting evidence within studies, we limited this bias. While not directly searched for through the search strategy, one Practice Guidance document was identified as part of this review; as guidance documents provide evidence-based recommendations for disease management, further research into guidance-specific evidence would be useful to understand the recommended NASH management options across countries and identify any discrepancies in recommendations.
There was a range of methodologies reported in the publications captured in this review, and a difference in the robustness of evidence must be acknowledged. The majority of the publications were narrative reviews, which did not report primary data regarding the efficacy and safety of pharmacological therapies. There was also This structured literature review found that NASH management currently focuses on dietary modification, exercise, and managing of comorbidities, which has shown positive results in patients with mildto-moderate fibrosis due to NASH. However, there is a significant lack of evidence on both short-and long-term outcomes with these management strategies, and evidence shows that they do not always provide the level of control needed to provide sustained improvements for patients with NASH. Several investigational treatments are currently in development but equally lack long-term safety and efficacy data-this reflects the relatively new research area of NASH pharmacological therapies and the fact that many studies are still ongoing. The majority of available and upcoming therapies focus on treating, halting or reversing NASH with mild-to-moderate fibrosis.
Very limited data were reported in advanced fibrosis due to NASH, with only 2 therapies showing improvements in this population.
Further research is needed in treating patients with advanced stages of fibrosis due to NASH, where the highest morbidity and mortality burden of NASH lies. 
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